De Meyer SF - Search Results

1

High intracellular iron oxide nanoparticle concentrations affect cellular cytoskeleton and focal adhesion kinase-mediated signaling.

Soenen SJ, Nuytten N, De Meyer SF, De Smedt SC, De Cuyper M. Soenen SJ, et al. Among authors: de meyer sf, de cuyper m, de smedt sc. Small. 2010 Apr 9;6(7):832-42. doi: 10.1002/smll.200902084. Small. 2010. PMID: 20213651

2

MRI assessment of blood outgrowth endothelial cell homing using cationic magnetoliposomes.

Soenen SJ, De Meyer SF, Dresselaers T, Vande Velde G, Pareyn IM, Braeckmans K, De Cuyper M, Himmelreich U, Vanhoorelbeke KI. Soenen SJ, et al. Among authors: de meyer sf, de cuyper m. Biomaterials. 2011 Jun;32(17):4140-50. doi: 10.1016/j.biomaterials.2011.02.037. Epub 2011 Mar 17. Biomaterials. 2011. PMID: 21419482

3

Restoration of plasma von Willebrand factor deficiency is sufficient to correct thrombus formation after gene therapy for severe von Willebrand disease.

De Meyer SF, Vandeputte N, Pareyn I, Petrus I, Lenting PJ, Chuah MK, VandenDriessche T, Deckmyn H, Vanhoorelbeke K. De Meyer SF, et al. Arterioscler Thromb Vasc Biol. 2008 Sep;28(9):1621-6. doi: 10.1161/ATVBAHA.108.168369. Epub 2008 Jun 12. Arterioscler Thromb Vasc Biol. 2008. PMID: 18556568 Free article.

4

Platelets at work in primary hemostasis.

Broos K, Feys HB, De Meyer SF, Vanhoorelbeke K, Deckmyn H. Broos K, et al. Among authors: de meyer sf. Blood Rev. 2011 Jul;25(4):155-67. doi: 10.1016/j.blre.2011.03.002. Epub 2011 Apr 14. Blood Rev. 2011. PMID: 21496978 Review.

5

New approaches for antithrombotic antiplatelet therapies.

Ulrichts H, Vanhoorelbeke K, Van De Walle G, Katsutani S, De Meyer S, Staelens S, Deckmyn H. Ulrichts H, et al. Curr Med Chem. 2004 Sep;11(17):2261-3. doi: 10.2174/0929867043364630. Curr Med Chem. 2004. PMID: 15379711 Review.

6

False positive results in chimeraplasty for von Willebrand Disease.

De Meyer SF, Pareyn I, Baert J, Deckmyn H, Vanhoorelbeke K. De Meyer SF, et al. Thromb Res. 2007;119(1):93-104. doi: 10.1016/j.thromres.2005.12.009. Epub 2006 Feb 2. Thromb Res. 2007. PMID: 16457874

7

Phenotypic correction of von Willebrand disease type 3 blood-derived endothelial cells with lentiviral vectors expressing von Willebrand factor.

De Meyer SF, Vanhoorelbeke K, Chuah MK, Pareyn I, Gillijns V, Hebbel RP, Collen D, Deckmyn H, VandenDriessche T. De Meyer SF, et al. Blood. 2006 Jun 15;107(12):4728-36. doi: 10.1182/blood-2005-09-3605. Epub 2006 Feb 14. Blood. 2006. PMID: 16478886 Free PMC article.

8

Development of monoclonal antibodies that inhibit platelet adhesion or aggregation as potential anti-thrombotic drugs.

De Meyer SF, Vanhoorelbeke K, Ulrichts H, Staelens S, Feys HB, Salles I, Fontayne A, Deckmyn H. De Meyer SF, et al. Cardiovasc Hematol Disord Drug Targets. 2006 Sep;6(3):191-207. doi: 10.2174/187152906778249536. Cardiovasc Hematol Disord Drug Targets. 2006. PMID: 17017902 Review.

9

The A/T1381 polymorphism in the A1-domain of von Willebrand factor influences the affinity of von Willebrand factor for platelet glycoprotein Ibalpha.

Szántó T, Schlammadinger A, Staelens S, De Meyer SF, Freson K, Pareyn I, Vauterin S, Hársfalvi J, Deckmyn H, Vanhoorelbeke K. Szántó T, et al. Among authors: de meyer sf. Thromb Haemost. 2007 Jul;98(1):178-85. Thromb Haemost. 2007. PMID: 17598011

10

Coronary artery in-stent stenosis persists despite inhibition of the von Willebrand factor--collagen interaction in baboons.

De Meyer SF, Staelens S, Badenhorst PN, Pieters H, Lamprecht S, Roodt J, Janssens S, Meiring M, Vanhoorelbeke K, Bruwer A, Brown S, Deckmyn H. De Meyer SF, et al. Thromb Haemost. 2007 Dec;98(6):1343-9. doi: 10.1160/th07-05-0335. Thromb Haemost. 2007. PMID: 18064334

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

130 results

Search Page